Trials / Completed
CompletedNCT03680378
Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)
A Phase I Open-Label, Single-Centre Study to Assess the Concentration of AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Allecra · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to measure and compare the concentration of AAI101 and cefepime in bronchial epithelial lining fluid (ELF) and plasma following administration of cefepime/AAI101 combination in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cefepime 2 gram | Combination of cefepime 2 gram with AAI101 1 gram |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2019-04-30
- Completion
- 2019-04-30
- First posted
- 2018-09-21
- Last updated
- 2020-07-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03680378. Inclusion in this directory is not an endorsement.